ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2213

Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases
Abstract Number: 2214

Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
Abstract Number: 2215

Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
Abstract Number: 2216

Expanding Reproductive Health Assessments in Rheumatic Diseases: A Comparative Analysis of Demographic and Disease-Specific Factors
Abstract Number: 2217

Improving Patient Counseling on Medication Safety During Reproductive Years
Abstract Number: 2218

Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study
Abstract Number: 2219

Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus
Abstract Number: 2220

Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Abstract Number: 2221

Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Abstract Number: 2222

Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
Abstract Number: 2223

Improving collaboration between rheumatology and OBGYN in the reproductive health care of patients with rheumatic disease
Abstract Number: 2224

Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Abstract Number: 2225

The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Abstract Number: 2226

Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications
Abstract Number: 2227

The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].